Rx00059 - Cetuximab


Interactive Drug Target Network

Interactive Bipartite Drug Repurposing Graph

Rx00059
Primary Indication
Secondary Indication

Disease prevalence from Electronic Health Records

Click row to show all

Disease A Disease B A∩B A∩¬B B∩¬A Odds-Ratio P-Value Adjusted P-Value
K-Ras mutation-negative (wild-type), epidermal growth factor receptor (EGFR)-expressing, metastatic colorectal cancer metastatic colorectal cancer 7288 7288 7288 553.639 0 0.0
metastatic squamous cell carcinoma of the head and neck Locally advanced squamous cell carcinoma of the head and neck 312 312 312 12932.449 0 0.0
Recurrent squamous cell carcinoma of the head and neck Locally advanced squamous cell carcinoma of the head and neck 312 312 312 12932.449 0 0.0
Locally advanced squamous cell carcinoma of the head and neck metastatic squamous cell carcinoma of the head and neck 312 312 312 12932.449 0 0.0
regionally advanced squamous cell carcinoma of the head and neck pancreatic cancer 75 3498 2521 34.317 8.41E-85 2.7e-81

Chemical, Pharmacological and Biological Annotations


ATC Code:
L01XC06
Category:
Antineoplastic Agents
Classification:
Kingdom:
Organic Compounds
Superclass:
Organic Acids
Class:
Carboxylic Acids and Derivatives
Subclass:
Amino Acids, Peptides, and Analogues
Indication:
For treatment of EGFR-expressing metastatic colorectal cancer in patients who are refractory to other irinotecan-based chemotherapy regimens. Cetuximab is also indicated for treatment of squamous cell carcinoma of the head and neck in conju...
Click to show more...
Pharmacodynamics:
Used in the treatment of colorectal cancer, cetuximab binds specifically to the epidermal growth factor receptor (EGFr, HER1, c-ErbB-1) on both normal and tumor cells. EGFr is over-expressed in many colorectal cancers. Cetuximab competitive...
Click to show more...
Description:
Epidermal growth factor receptor binding FAB. Cetuximab is composed of the Fv (variable; antigen-binding) regions of the 225 murine EGFr monoclonal antibody specific for the N-terminal portion of human EGFr with human IgG1 heavy and kappa l...
Click to show more...
Mechanism:
Cetuximab binds to the epidermal growth factor receptor (EGFr) on both normal and tumor cells. EGFr is over-expressed in many colorectal cancers. Cetuximab competitively inhibits the binding of epidermal growth factor (EGF) and TGF alpha, t...
Click to show more...

Adsorption, Distribution, Metabolism, Excretion and Toxicity


Not Available from DrugBank


Contact Us:
Please contact us if you have questions or comments about RepurposeDB. You can also contact us if you need help in submitting your drug repositioning investigation to RepurposeDB.


Dudley Laboratory
Department of Genetics and Genomic Sciences
Icahn Institute for Genomics and Multiscale Biology
Icahn School of Medicine at Mount Sinai
One Gustave L. Levy Place, Box 1498
Manhattan, New York City, NY
repurposedb@dudleylab.org